Association of Skin with the Pathogenesis and Treatment of Neurodegenerative Amyloidosis by Audra L. Clos et al.
REVIEW ARTICLE
published: 20 January 2012
doi: 10.3389/fneur.2012.00005
Association of skin with the pathogenesis and treatment of
neurodegenerative amyloidosis
Audra L. Clos1, Rakez Kayed 2,3,4 and Cristian A. Lasagna-Reeves2,3,4*
1 Department of Dermatology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA
2 George P. and CynthiaWoods Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA
3 Department of Neurology, University of Texas Medical Branch, Galveston, TX, USA
4 Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA
Edited by:
Philip P. Foster, University of Texas
Medical Branch, USA
Reviewed by:
Daniel Michaelson, Tel-Aviv University,
Israel
Salahadin Abdi, Harvard Medical
School, USA
Philip P. Foster, University of Texas
Medical Branch, USA
*Correspondence:
Cristian A. Lasagna-Reeves,
University of Texas Medical Branch,
301 University Blvd, Medical
Research Building, Room 10.130,
Galveston, TX 77555, USA.
e-mail: calasagn@utmb.edu
Amyloidosis are a large group of conformational diseases characterized by abnormal pro-
tein folding and assembly which results in the accumulation of insoluble protein aggregates
that may accumulate systemically or locally in certain organs or tissue. In local amyloido-
sis, amyloid deposits are restricted to a particular organ or tissue. Alzheimer’s, Parkinson’s
disease, and amyotrophic lateral sclerosis are some examples of neurodegenerative amy-
loidosis. Local manifestation of protein aggregation in the skin has also been reported.
Brain and skin are highly connected at a physiological and pathological level. Recently sev-
eral studies demonstrated a strong connection between brain and skin in different amyloid
diseases. In the present review, we discuss the relevance of the “brain–skin connection”
in different neurodegenerative amyloidosis, not only at the pathological level, but also as a
strategy for the treatment of these diseases.
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INTRODUCTION
Amyloidosis is not a single disease, but rather a variety of differ-
ent pathological processes resulting in the deposition of β-pleated
sheet ﬁbrils formed from various proteins by several different
pathogenic mechanisms (Husby, 1992). Virchow introduced the
term “amyloidosis” to designate an amorphous material that had
a similar staining property as cellulose, a polysaccharide, not a
protein at all (Kyle and Gertz, 1990; Cohen, 1993). Currently vari-
ous stains have traditionally been used for the histologic detection
of amyloid such as crystal violet, thioﬂavin S, hematoxylin–eosin,
and Congo red stains. Congophilia is the main characteristic that
is used to describe amyloid, and under polarized light amyloid
displays apple-green birefringence due to its β-pleated sheet con-
formation (Kyle andGertz, 1990; Rocken et al., 1996).Amyloidosis
is an example of a disease caused by malfunctioning proteins
and is thus referred to as a conformational or protein misfolding
disease. The group of peptides and proteins capable of form-
ing amyloid ﬁbrils is very diverse (Guijarro et al., 1998; Chiti
et al., 1999; West et al., 1999; Sipe and Cohen, 2000; Lopez De
La Paz et al., 2002). This group consists not only of proteins
involved in amyloid deposits in vivo (Sipe and Cohen, 2000),
but also of non-pathogenic (von Bergen et al., 2000; Azriel and
Gazit, 2001) and designed peptides and proteins (West et al., 1999;
Lopez De La Paz et al., 2002). The conformational diseases or
amyloid diseases include Alzheimer’s disease (AD), Parkinson dis-
eases, amyotrophic lateral sclerosis (ALS), type 2 diabetes mellitus,
and various forms of cutaneous amyloidosis (Botelho and Lupi,
2008). Hence, the question arose whether there may be evidence
supporting a link between cutaneous manifestations of amyloid
deposits and neurodegenerative amyloidosis. This review aims to
address this question and give a novel perspective on the relation
of amyloid in skin and brain.
CUTANEOUS AND NEURODEGENERATIVE AMYLOIDOSIS
A vast range of human diseases arise from the failure of a spe-
ciﬁc peptide or protein to adopt or remain in its native functional
conformational state. These pathologic conditions collectively are
referred to as protein conformational diseases. The largest group
of conformational diseases is associated with the conversion of
speciﬁc peptides or proteins from their soluble functional state
to toxic aggregates that are deposited in the tissues (Stefani and
Dobson, 2003). Amyloidoses are a large group of conformational
diseases in which protein aggregates accumulate either systemi-
cally or locally in certain organs or tissues (Tillement et al., 2009).
In local amyloidosis, amyloid deposits are restricted to a partic-
ular organ or tissue. Local amyloidosis can be broadly grouped
into neurodegenerative conditions in which aggregation occurs in
the brain, including Alzheimer’s, Parkinson’s diseases (PD), and
ALS (Chiti and Dobson, 2006; Meersman et al., 2006), and non-
neuropathic localized amyloidosis, in which aggregation occurs in
a single type of tissue other than the brain, i.e., type II diabetes
(pancreas) and Cutaneous amyloidosis (skin; Chiti and Dobson,
2006). Secondary cutaneous amyloidosis is an entity of systemic
amyloidosis in which amyloid can be secondarily located in the
skin and others organs. In the case of the secondary cutaneous
amyloidosis, the amyloid proteinA (AA) is involved (Katsikas et al.,
2008). Also, amyloid light chain has been involved in several cases
of systemic amyloidosis in the skin (Feito-Rodriguez et al., 2008).
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Primary cutaneous amyloidosis is a local amyloidosis in which
amyloid deposits are restricted to the skin. This disease has been
classiﬁed into three types: macular amyloidosis, lichen amyloido-
sis, and nodular amyloidosis (Bhat et al., 2009; Schwendiman et al.,
2009). Primary cutaneous nodular amyloidosis is thought to be a
plasma cell dyscrasia, where amyloid light chain is involved and
diagnosis is based on the absence of clonal plasma cell prolifer-
ation in the bone marrow; however some patients thought to be
afﬂicted with only a localized version of this disease on long-term
follow-up did indeed develop systemic amyloidosis. It remains
unclear if the disease was always systemic with early cutaneous
manifestations, or if it was a disease with a low-grade potential to
develop into a systemic disease. In the speciﬁc case of macular and
lichenoid amyloidoses, it is believed that altered keratin is themain
component of the amyloidogenic material (Feito-Rodriguez et al.,
2008) and that epidermal cells are closely related to the deposition
of amyloid (Black, 1971; Black and Jones, 1971). Work done by
Hashimoto and Kumakiri (1979) more than 20 years ago demon-
strated the ﬁbrillar degeneration of epidermal cells and dropping
off of the ﬁbrillar bodies into the dermis; the authors speculated
that these ﬁbrillar bodies were modiﬁed by the surrounding his-
tiocytes and or ﬁbroblasts. This theory of amyloidosis has been
named the ﬁbrillar body theory (Hashimoto and Kumakiri, 1979;
Kumakiri and Hashimoto, 1979; Hashimoto and Kobayashi, 1980;
Kobayashi and Hashimoto, 1983; Eto et al., 1984). The second the-
ory of deposition is the secretion theory. This theory states that in
macular and lichenoid amyloidosis, the amyloid is produced in the
interface of the epidermis and dermis by living basal keratinocytes,
which produce the precursor of amyloid because of disturbed ker-
atin metabolism (Yanagihara and Mori, 1982). Recent research
suggests that preﬁbrillar aggregates, soluble oligomers, rather than
ﬁbrils per se are the most potent mediators of cytotoxicity (Her-
czenik and Gebbink, 2008). It has also been shown that toxic
oligomers share a common structure, and that in consequence
there is a generic pathogenic mechanism (Bucciantini et al., 2004;
Pastor et al., 2008).However, themechanismof amyloid formation
and toxicity is still unknown; thus, there is not an effective treat-
ment for any of the conformational diseases. Given that a common
pathogenic mechanism may underlie in all of these diseases, treat-
ments that target protein conformation could be applicable in a
variety of contexts (Glabe, 2006; Glabe and Kayed, 2006). At the
molecular level several models have been postulated to explain the
common mechanism of amyloidogenesis in protein misfolding
disease. Nucleation-dependent ﬁbrillation is the prevalent model
for assessing the self-assembly process. This model postulated that
it is necessary to have a nucleus or seed to initiate the ﬁbrilla-
tion process. Once the nucleus is formed, ﬁbril growth is thought
to proceed rapidly by further association of either monomers or
oligomers with the nucleus (Jarrett and Lansbury, 1993; Harper
and Lansbury, 1997; Wood et al., 1999). Recently another mech-
anism was proposed for amyloidogenesis: double-concerted ﬁb-
rillation (Bhak et al., 2009a,b). Based on this model, the amy-
loid ﬁbril formation is achieved via two consecutive, concerted
associations of monomers and subsequently formed oligomeric
granular species, in which the oligomeric species act as a growing
unit for the ﬁbril formation in the absences of a seed. Amyloid
species can transmit conformational changes in homologous and
heterologous proteins, mechanisms denominated as seeding and
cross-seeding, respectively (Westermark et al., 2009). Despite a
lack of similarity in the functional properties or in the primary,
secondary, or tertiary structures among these proteins, the amy-
loids formed from them share a common ultra-structure (Rochet
and Lansbury, 2000; Fu et al., 2004; Nelson et al., 2005). Sev-
eral studies have described this process in vitro (Giasson et al.,
2003; Lasagna-Reeves et al., 2010). However, only a few studies
have described the presence of two different amyloid proteins in
the same organ or tissue in human patients. For example, amy-
loid β-peptide (Aβ) amyloid and PrPsc were detected in a single
plaque in patients with Gerstmann–Sträussler syndrome (Miya-
zono et al., 1992). In another study, aggregate forms of kappa-light
chain and β2-microglobulin were colocalized in a patient with
multiple myeloma (Takahashi et al., 1996). Aβ amyloid has also
been colocalized with light chain immunoglobulin aggregates in
diseased leptomeningeal and cortical vessels in patients with spon-
taneous intracranial hemorrhage (Galuske et al., 2004). In a recent
publication, we have shown how to induce amyloid formation in
the skin of wild-type mice (Clos et al., 2010). In that study we illus-
trated that the intradermal administration of certain amyloid can
induce the aggregation of heterologous proteins (Clos et al., 2010).
This study gave direct evidence of the cross-seeding mechanism in
the skin. Even more, Heiko Braak and Kelly Del Tredici proposed
in 2003 that PD begins in the gut, then slowly makes its way to
the brain and spreads to different regions (Braak et al., 2003). The
authors speciﬁcally proposed that the disease could start in the gut
induced by a virus or other pathogen, and move along the vagus
nerve in an upstream, or retrograde, direction toward the brain.
One idea that is gaining momentum is that, instead of a virus or
some other agent spreading through the nervous system to induce
the pathology associated with PD, the pathology itself, in other
words, the misfolded form of α-synuclein, is what spread from
one neuron to the next (Braak et al., 2003; Jang et al., 2009). These
studies demonstrated how the presences of amyloidogenic mater-
ial outside the central nervous system can have a direct impact in
neurodegenerative amyloidosis.
These ﬁndings reveal that there may be a connection of cuta-
neous forms of amyloidoses and neurodegenerative amyloidoses.
Furthermore, skin physiology is widely altered in these types of
diseases.
FUNCTIONAL AMYLOIDS
An increasing number of examples suggest that amyloid ﬁbers, or
amyloidogenic intermediates, can be used to facilitate a particular
physiological task (Fowler et al., 2007; Greenwald and Riek, 2010).
These functional amyloids have been found in many organisms,
including bacteria, fungi, and mammals (Chiti and Dobson, 2006;
Fowler et al., 2007). Well-studied functional amyloid in Homo
sapiens includes Pmel17, which serves as a structural scaffold for
covalent polymerization of molecules during melanin assembly.
It has recently been shown that peptide and protein hormones in
secretory granules of the mammalian endocrine system are stored
in an amyloid-like cross-β-sheet-rich conformation (Maji et al.,
2009). The natural storage of hormones in amyloid-like structures
does not produce any toxic effect to neuronal cells. Hydrophobins
are key components of fungal coats (e.g., Aspergillus fumigatus),
Frontiers in Neurology | Dementia January 2012 | Volume 3 | Article 5 | 2
Clos et al. Skin and treatment of neurodegenerative amyloidosis
and in bacteria curlin subunits (csgA) is necessary for bioﬁlm
formation and host invasion. In yeast several functional amy-
loidogenic proteins have been identiﬁed, such as Ure2p, Sup35p,
Rnq1p, and adhesins which is involved in cellular aggregation
(Chiti and Dobson, 2006; Fowler et al., 2007; Wang et al., 2007;
Epstein and Chapman, 2008; Maurer-Stroh et al., 2010; Ramsook
et al., 2010). Other examples of functional amyloids in nature
includes silkmoth chorion protein, ﬁsh chorion proteins, and
type I antifreeze protein (AFP, ice-structuring protein preventing
ice growth) of winter ﬂounder (Iconomidou and Hamodrakas,
2008). Many of these functional amyloids are involved in pro-
tection from environmental inﬂuences, for example Pmel17 in
human melanin assembly to prevent UV-damage, AFP in winter
ﬂounder to protect from ice crystals. Again, this shows that we
are far from really understanding the underlying processes. How-
ever, as shown in this paragraph, there are functional amyloids
in both skin and brain (Fowler et al., 2007; Greenwald and Riek,
2010).
SKIN–BRAIN CONNECTION
As of late there is increasing evidence for the “brain–skin connec-
tion.” The skin is a highly innervated organ and has been coined
a diffuse brain (Urpe et al., 2005). Many neuropeptides originate
in the skin, including catecholamines, substance P, calcitonin gene
related peptide (CGRP), vasoactive intestinal peptide (VIP), and
nerve growth factor (NGF). In psoriasis it has been shown that
activation of the autonomic nervous system increases neuropep-
tides and is implicated in the development of psoriatic lesions. It
has also been found that psoriatic plaques have increased nerve
ﬁber density, and that high expression of NGF mediates T cell and
keratinocyte proliferation,mast cell migration and degranulation,
and memory T cell migration; all important in the pathogenesis
of psoriasis (Halevy and Livni, 1993; Steinkraus et al., 1993; Ray-
chaudhuri et al., 2000). Also important in psoriasis, is the impact
of negative psychosocial consequences, including stress, depres-
sion, and mood disorders, which in some cases have been shown
to precede the diagnosis of psoriasis as well as appear prior to the
onset of disease ﬂares (Fortune et al., 2002, 2005). In atopic der-
matitis interactions between mast cells, the nervous system, and
neuropeptides have also been implicated in the disease process
and in murine models of sound-produced stress lends support to
a NGF-Substance P mast cell communication in neurogenic skin
inﬂammation (Arck et al., 2003; Jarvikallio et al., 2003; Peters et al.,
2004).
Many other dermatologic conditions and diseases are linked to
neuroimmunological stress such as pruritus, hyperhidrosis, ﬂush-
ing, seborrhoeic eczema, prurigo nodularis, lichen planus, and
alopecia areata (Biro et al., 2005) In fact the hair follicle is one of
the most hormone sensitive tissues in human physiology. It is very
sensitive to stress associated hormones such, as cortisol releasing
hormone (CRH), cortisol, prolactin, catecholamines, among oth-
ers. The hair follicle is not only an endpoint for neuropeptides,
but also a source (Slominski et al., 2000). It is not surprising that
stress has been implicated as a major aggravating factor in hair loss
(Arck et al., 2003).
As discussed previously pruritus is linked to neuroimmunolog-
ical stress; endpoints of pruritus leads to scratching (itch-scratch
cycle), scratching leads to prolonged inﬂammation and inﬂam-
mation may induce conformational changes of proteins. Certain
proteins, in the skin, are more susceptible to conformational
changes, an example of this is cytokeratin; implicated in the patho-
genesis of macular and lichenoid amyloidosis. Primary localized
cutaneous amyloidosis (PLCA) is a notoriously itchy skin condi-
tion associated with amyloid deposition in the superﬁcial dermis
(Brownstein and Helwig, 1970). Of note it is reported that often
pruritus is the ﬁrst symptom reported in both familial and spo-
radic forms of PLCA, implicating the importance of pruritus and
the nervous system in the pathogenesis of this disease (Brownstein
and Helwig, 1970).
ALZHEIMER’S DISEASE AND SKIN
Alzheimer’s disease, is the most common cause of dementia in
the elderly, is marked by a progressive degeneration of limbic and
cortical brain structures, mainly in the temporal lobe. By 2050
the number of people with AD is expected to triple (Hebert et al.,
2001; Editorial, 2010), placing an enormous burden on health care
and social care system. AD is a neurodegenerative disorder that is
characterized clinically by progressive loss of memory, language
problems, social withdrawal, deterioration of executive functions,
and eventually culminates in death (Citron, 2002). Most AD cases
are sporadic, with multiple risk factors, such as aging, environ-
mental stress, and diet, suggested to play critical pathogenic roles.
The remaining AD cases, which account for 5–10% of total AD
cases, are rare, but inherited from one generation to the next and
are referred to as familial AD (FAD). The major neuropathologi-
cal features of AD are synaptic and neuronal degeneration and the
presence of amyloid plaques and neuroﬁbrillary tangles (NFTs).
The major protein component of the plaques is the Aβ, which
is a 39–43 amino acid peptide that is found by a much larger
transmembrane protein, the amyloid precursor protein (APP;
Selkoe, 1994), whereas NFTs are composed of hyperphosphory-
lated forms of the microtubule-binding protein tau. These two
insoluble protein aggregates are believed to play critical roles in
the neurodegenerative process.
There are several ﬁndings of altered skin physiology in patients
with AD. In AD presenilin 1 (PS-1) is an enzyme that is essen-
tial for proteolytic processing of APP and has been implicated in
skin cancer in animals (Xia et al., 2001). PS-1 is also involved in
epidermal growth factor receptor (EGRF) regeneration and a par-
tial loss of presenilin-1 may lead to the development of seborrhea
keratoses and inﬂammatory skin conditions (Tournoy et al., 2004;
Repetto et al., 2007). Antioxidant defenses in skin ﬁbroblasts from
patients with familial AD were shown to be lower when compared
to control patients (Cecchi et al., 2002). In patients with AD, it is
also been discovered that cutaneous vascular function is altered,
just as in the brain (Kalman et al., 2002; Khalil et al., 2007), as well
as mastocyte expression of β amyloid and tau protein (Soininen
et al., 1992; Okada et al., 1994; Wen et al., 1994; Kvetnoi et al.,
2003).
In addition to the connection betweenAD and skin pathophys-
iology, the skin is also being used as a vector to deliver medication
in AD patients. The Rivastigmine patch is the ﬁrst transdermal
treatment to be approved for AD. Rivastigmine is an established
cholinesterase inhibitor indicated for the treatment of mild to
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moderate dementia of AD. Two drug classes have been approved
for the treatment of AD in theUS: cholinesterase inhibitors andN -
methyl-d-aspartate-receptor antagonists. Several of rivastigmine’s
chemical characteristicsmake it appropriate for transdermal patch
delivery; the drug can pass through the skin with ease, entering
the blood stream and crossing the blood brain barrier (Nitti et al.,
2006). Compared to rivastigmine capsules the patch shows less
ﬂuctuation in plasma concentration and fewer GI side effects,
making this drug more tolerable for patients and lowering the
discontinuation rate (Rosler et al., 1999; Mercier et al., 2007; Win-
blad et al., 2007a). The patch and oral form of this medication
show similar efﬁcacy, other than less gastrointestinal side effects
than the oral form, there is also a caregiver preference for the
patch form of Rivastigmine (Blesa et al., 2007; Winblad et al.,
2007b).
Several experimental immunizations, in animal models, are
also utilizing the skin and nasal mucosa to deliver β amyloid.
Nikolic et al. (2007) demonstrated that transcutaneous immu-
nization with aggregated β amyloid peptide with adjuvant cholera
toxin, lead to high titers of Aβ antibodies and lead to signiﬁcant
decreases in cerebral amyloid β levels. Other experiments show
that Aβ derived peptides, with an adjuvant, delivered intranasally
to mucosal epithelial tissues results in effective clearance of Aβ
plaques and improvement of cognitive function in animal models
of AD (Maier et al., 2005, 2006). The skin is a well known effective
route for vaccination of peptide based vaccines; strong humoral
and cellular immune activity has been summoned secondary to
trans cutaneous vaccinations. This can be attributed to the diverse
populations of resident antigen presenting cells and other immune
cells in the dermis (Beignon et al., 2005; Itoh and Celis, 2005; Dell
et al., 2006; Giudice and Campbell, 2006).
PARKINSON’S DISEASE AND SKIN
Parkinson’s disease is a progressive and devastating neurodegen-
erative disorder, affecting 1% of individuals over 60 years old
(Samii et al., 2004). The three cardinal clinical features of PD are
rigidity, resting tremor and bradykinesia, and these occur when
approximately 50% of dopaminergic neurons projecting from the
substantia nigra pars compacta (SNc) to the striatum are lost
(Samii et al., 2004). The neuropathological hallmark of the disease
is the presence in surviving SNc neurons of intracellular inclu-
sions known as Lewy bodies (LBs), which are composed mainly of
ﬁbrillar form of the protein α-synuclein (Spillantini et al., 1997;
Samii et al., 2004). The pathology of PD is not solely conﬁned to
the nigrostriatal pathway because LBs are also found in the cor-
tex, amygdala, locus coeruleus, and peripheral autonomic system
(Dickson et al., 2009;Wolters, 2009). Dysfunction of these extran-
igral neuronal populations and the presence of LBs correlate with
the non-motor manifestations of PD, including autonomic, sleep,
and olfactory dysfunctions, and these can precede the appearance
of motor symptoms (Dickson et al., 2009; Wolters, 2009).
Interestingly there is a higher than expected frequency of the
development of melanoma, a malignant tumor of melanin man-
ufacturing cells in the skin, in patients with PD, and even more,
melanoma patients are more likely to have PD. Malfunctions in
melanin correlate with various skin cancers, such as melanoma,
whereas abnormalities in neuromelanin correlate with PD, this
proposes that melanin has a function in predisposition to devel-
opment of PD and melanoma. Pigmentation genes determine the
amount and type of melanin, such genes that are shared in these
two diseases, include those that encode tyrosinase and hydroxylase
(Halaban et al., 1997). Melanocytes and dopaminergic neurons
contain different substances, but they both share a precursor of
tyrosine and make 3,4 dihydroxyphenylalanine (DOPA). Thus
genes involved in the synthesis of dopamine and melanin appear
to be a likely source of the relationship between PD and melanoma
(Gudbjartsson et al., 2008; Duffy et al., 2010).
As we already mentioned, α-synuclein plays a large role in the
pathogenesis of PD; it accumulates within SN neurons (Spillan-
tini et al., 1997). It has been shown that α-synuclein is increased
in the cutaneous peripheral nerves of PD patients when compared
to other neurodegenerative diseases (Paisan-Ruiz et al., 2009).
α-Synuclein is widely expressed in melanoma cells. Even more
melanoma cells that do express high levels of α-synuclein do not
produce much melanin pigment, and it is thought that melanin
pigment is protective against malignant melanomas. This could be
a plausible explanation for why patients with PD have an increased
risk for melanoma (Paris et al., 2001).
As in AD, in PD, the skin is also being utilized to deliver
Rivastigmine, an inhibitor of acetylcholinesterase and butyryl-
cholinesterase, transdermally. Cholinergic deﬁcits are pronounced
in patients who have dementia related with PD. In a study per-
formed by Emre et al. (2007) oral Rivastigminewas associatedwith
moderate improvements in dementia associatedwithPD.Rivastig-
mine patch is also approved for treatment in PD and has been
shown to have similar efﬁcacy and improved tolerability as com-
pared to the oral form of the drug (Mercier et al., 2007; Winblad
et al., 2007a).
It has also been shown that the transdermal delivery of
dopamine agonist, Rotigotine, is well tolerated and is beneﬁcial in
the treatment of early and late stage PD. Rotigotine has been also
shown to improve sleep as well as early morning motor symptoms
(Trenkwalder et al., 2011).
AMYOTROPHIC LATERAL SCLEROSIS AND SKIN
Amyotrophic lateral sclerosis is a neurologic diseasewith an annual
incidence rate of approximately 1 in 100,000 (Morrison and Mor-
rison, 1999). There are both sporadic and familial forms of the
disease, with familial ALS accounting for approximately 5% of
cases. The symptoms and pathology of patients with the familial
form of ALS are identical to those of patients with the sporadic
form, suggesting that the mechanisms of neurodegeneration for
sporadic and familial ALS share common components. The early
symptoms of ALS are muscle atrophy, weakness, and fascicula-
tions. The disease progresses over an average of 5 years, leading to
paralysis and premature death (Morrison and Morrison, 1999).
Pathologically, ALS is characterized by extensive loss of lower
motor neurons in the spinal cord andbrainstem,atrophy of ventral
roots, degeneration of upper motor neurons in the motor cortex,
corticospinal tract degeneration, somatic and axonal inclusions of
aberrant neuroﬁlament proteins (NFP), and reactive astrocytosis
(Hirano, 1991; Leigh and Swash, 1991).
Superoxide dismutase 1 (SOD1) is an antioxidant protein
expressed abundantly and ubiquitously (Zelko et al., 2002) and
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since the discovery in 1993 that mutations in SOD1 cause ALS
(Deng et al., 1993; Rosen, 1993) a further 140 mutations have
since been found scattered throughout the 153 amino acid Cu/Zn-
homodimer. Mutations are mostly substitutions of single amino
acid residues although some deletions, insertions, and C-terminal
truncations have been identiﬁed. SOD1 mutations are known to
be causative in 10–20% fALS cases, and have been observed in
2% sporadic cases (Dion et al., 2009). The presence of inclusion
bodies or aggresomes is one of the neuropathological hallmarks
of ALS. Spinal cord sections from SOD1-fALS patients have
been examined by immunohistochemistry and found to con-
tain aggregates that are reactive to anti-SOD1 antibodies (Kato,
2008). More recent evidence has shown that in non-SOD1 ALS
(fALS and sALS), aggregates also contain SOD1 (Shibata et al.,
1994; Matsumoto et al., 1996), and there is no marked differ-
ence in disease presentation and progression, either clinically or
neuropathologically, between fALS and sALS (Gros-Louis et al.,
2006).
FIGURE 1 | Linking skin and brain amyloidosis. Skin and brain are
connected in several ways. Based on the published data describing the
spread amyloid deposits, it is feasible that cutaneous amyloid spread to other
organs including the brain (1) or vice versa (2). This strong connection
between both organs makes it a viable and attractive option for the treatment
several neurodegenerative amyloidosis via transdermal administration of
therapeutics (3). The skin–brain connection not only involved amyloid
treatment and formation, but also has an important relevance in several
dermatologic conditions linked to neuroimmunological stress, in which an
increase of neuropeptides in the skin (4) or the brain (5) has been reported.
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Sporadic ALS is a degenerative disorder of the upper and
lower motor neurons. There is no determined cause for this dis-
ease. Interestingly it was reported in 1996 by Kolde et al. (1996)
that there was deposition of amyloid β protein in the skin of
patients with ALS, but not in control matched patients. Findings
from Tamaoka and colleagues (Tamaoka et al., 2000) suggest that
changes in the extracellular matrix in the skin of ALS patients may
facilitate aggregation and deposition of Amyloid β in the skin. This
conclusion was extracellular matrix components including type 4
collagen and glycosaminoglycans have been found and these com-
ponents affect processing and accumulation of Amyloid β in the
human brain (Asami-Odaka et al., 1995; Ono et al., 1998a,b).
In ALS skin-like and spherical inclusions within the somato-
dendritic compartment of vulnerable neurons is a hallmark of
the disease process. A large constituent of the inclusions is a
phosphorylated, aggregated, and ubiquitinated intranuclear pro-
tein, Transactivation-responsive DNA-binding protein-43 (TDP-
43; Arai et al., 2006; Davidson et al., 2007; Geser et al., 2009).
TDP-43 is a transcription-related protein that is localized within
the cell nucleus; it may act as a transcription repressor of nuclear
bodies through communication with survival motor neuron pro-
tein (Neumann et al., 2006). It has also been shown that missense
mutations in the TDP-43 gene have been discovered in familial and
sporadic cases of ALS, lending credence to the role that TDP-43
plays in the degeneration and cell death of motor neurons (Gitcho
et al., 2008; Sreedharan et al., 2008; Daoud et al., 2009). Suzuki
et al. (2010) investigated the skin from Sporadic ALS patients, and
found that there was a high frequency of TDP-43 positive cells.
Furthermore they reported that the skin from patients with longer
standing ALS was more immunoreactive for TDP-43 than patients
who had not been afﬂicted with the disease for as long a period of
time. Based on their discovery, it may be postulated that a com-
mon disease process may be occurring in the skin and in the motor
neurons, with regards to accumulation of TDP-43 (Suzuki et al.,
2010).
Matrix metalloproteinase (MMP) are a family of Zn2+
endopeptides that have the ability to digest elements of the extra-
cellular matrix such as collagen (Kolde et al., 1996). In ALS
there is an increased activity of MMPs in the CNS (Beach et al.,
1986). Reports from experiments in mutant SOD1 transgenic
mice have implicated a role of MMPs in the early stage of the
disease and that inhibition of certain MMPs may serve a protec-
tive role in ALS (Vincenti and Brinckerhoff, 2007). It has been
observed that patients with ALS do not develop many bedsores
(Furukawa and Toyokura, 1976). Reports from skin biopsies of
patients withALS show altered skin ultra-structure with decreased
collagen crosslinking and thinner collagen ﬁber diameter; this
could possibly be due to increased MMP activity in the skin
(Bonnefont-Rousselot et al., 2000; Lorenzl et al., 2006; Fang et al.,
2009). Fang et al. (2010) discovered increased MMP-9 activity
in the skin of ALS patients, as well as in the CNS, thus linking
the pathophysiology of neurodegeneration and skin alterations
in ALS.
Several systemic treatments, utilizing subcutaneous injections,
have been proposed inALS, although currently there is no curative
treatment to date. Ciliary neurotrophic growth factor (CNTF) is
a neurotrophic factor which has been proven to promote motor
neuron survival in cell cultures and in murine ALS models. Two
randomized clinical trials with ALS patients utilized this growth
factor, but no signiﬁcant efﬁcacy was observed (Miller et al., 1996;
Bongioanni et al., 2004).
Insulin like growth factor I (IGF-I) is a peptide with neu-
rotrophic effects; the recombinant form of this peptide has also
been injected subcutaneously into patients with ALS is several
clinical trials with varying results (Lai et al., 1997; Borasio et al.,
1998;Mitchell et al., 2007). In neuropathymodels using transgenic
animals, beneﬁcial outcomes have been reported in a number of
studies (Mitchell et al., 2007).
CONCLUSION
There is now solid evidence for the existence of a deﬁned “brain–
skin connection,”which includes the over-activation of neuropep-
tides in psoriasis and atopic dermatitis and several dermatologic
conditions linked to neuroimmunological stress (Fortune et al.,
2002; Biro et al., 2005). Several studies discussed in the present
review, have suggested that cutaneous amyloidosis shares a com-
mon amyloidogenesis and pattern of deposition similar to other
well characterized amyloid-related diseases and provide the ﬁrst
evidence showing that all these diseases share common amyloido-
genic structures associated with a generic pathogenic mechanism
(Bucciantini et al., 2004; Pastor et al., 2008; Clos et al., 2011).
Even more, if we take in consideration the newly published data
which demonstrates that amyloidogenic proteins can spread in
a seeding mechanism (Westermark et al., 2009) and may possi-
bly start outside the central nervous system (Braak et al., 2003).
In light of the evidence discussed in this review, is not illogical
to think that the presence of amyloid in the skin can induce
protein aggregation in the brain either directly of indirectly. As
indicated in Figure 1, the “brain–skin connection” may have a
physiological relevance in terms of amyloid diseases, their patho-
genesis, and progression. This clear and direct axis can been
explored as a safe and simple way to deliver different med-
ications to treat neurodegenerative amyloidosis via cutaneous
administration.
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